株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

T細胞療法の世界市場:規模、シェア、および動向 - モダリティ、療法タイプ、適応症、地域、セグメント別予測(2019年~2026年)

T-Cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), And Segment Forecasts, 2019 - 2026

発行 Grand View Research, Inc. 商品コード 913840
出版日 ページ情報 英文 200 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
T細胞療法の世界市場:規模、シェア、および動向 - モダリティ、療法タイプ、適応症、地域、セグメント別予測(2019年~2026年) T-Cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-Cell, Tumor Infiltrating Lymphocytes), By Indication (Hematologic Malignancies, Solid Tumors), And Segment Forecasts, 2019 - 2026
出版日: 2019年09月25日 ページ情報: 英文 200 Pages
概要

世界のT細胞療法市場は、2026年までの間に15.4%のCAGRで拡大する見通しで、2026年には75億1,000万米ドルに達すると予測されています。

当レポートは世界のT細胞療法市場について調査しており、市場の動向や見通し、モダリティ・療法タイプ・適応症・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査方法

  • 情報調達
  • 情報またはデータ分析
  • 市場の定式化および検証

第2章 エグゼクティブサマリー

  • 競合の環境
  • 市場のスナップショット
  • セグメントの見通し

第3章 市場変数、動向、および範囲

  • 療法タイプの普及率および成長の見通しのマッピング
  • 市場力学
  • 規制の状況
  • 養子細胞療法(ACT)の価格設定および支払いモデル
  • 特許の風景
  • 取引、資金調達、提携および協業
  • パイプライン分析
  • 企業の地理的マッピング
  • CD19標的CAR-T細胞療法およびその他のT細胞療法の競合状況
  • SWOT分析:要因別(政治、法律、経済、技術)
  • 産業分析:ポーターのファイブフォース分析

第4章 市場分析:モダリティ別

  • 動向分析
  • 研究
  • 商品化

第5章 市場分析:療法タイプ別

  • 動向分析
  • CAR T細胞療法
  • T細胞受容体(TCR)ベース
  • 腫瘍浸潤リンパ球(TIL)ベース

第6章 市場分析:適応症別

  • 動向分析
  • 血液悪性腫瘍
    • リンパ腫
    • 白血病
    • 骨髄腫
  • 固形腫瘍
    • 黒色腫
    • 脳および中枢神経系
    • 肝臓がん
    • その他

第7章 市場分析:地域別

  • 市場シェア(2018年・2026年)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 戦略の枠組み
  • 企業プロファイル
図表

List of Tables

  • TABLE 1 Summary of finalized, proposed, and modeled payment adjustments, 2019 - 2023
  • TABLE 2 Licensing deals in T-cell therapy space
  • TABLE 3 Merger & acquisition deals in T-cell therapy space
  • TABLE 4 Collaboration & partnerships in T-cell therapy space
  • TABLE 5 CAR T-cell target antigens in US trials
  • TABLE 6 CAR T-cell target antigens in China trials
  • TABLE 7 Competitive landscape for CD 19-directed CAR T Therapies in r/r lymphoma and leukemia
  • TABLE 8 CAR T-cell targets under investigation for hematologic malignancies
  • TABLE 9 North America T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 10 North America T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 11 North America T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 12 North America T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 13 North America T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 14 U.S. T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 15 U.S. T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 16 U.S. T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 17 U.S. T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 18 U.S. T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 19 Canada T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 20 Canada T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 21 Canada T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 22 Canada T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 23 Canada T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 24 Europe T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 25 Europe T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 26 Europe T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 27 Europe T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 28 Europe T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 29 Germany T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 30 Germany T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 31 Germany T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 32 Germany T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 33 Germany T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 34 U.K. T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 35 U.K. T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 36 U.K. T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 37 U.K. T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 38 U.K. T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 39 Asia Pacific T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 40 Asia Pacific T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 41 Asia Pacific T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 42 Asia Pacific T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 43 Asia Pacific T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 44 Japan T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 45 Japan T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 46 Japan T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 47 Japan T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 48 Japan T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 49 China T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 50 China T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 51 China T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 52 China T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 53 China T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 54 Latin America T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 55 Latin America T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 56 Latin America T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 57 Latin America T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 58 Latin America T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 59 Brazil T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 60 Brazil T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 61 Brazil T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 62 Brazil T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 63 Brazil T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 64 MEA T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 65 MEA T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 66 MEA T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 67 MEA T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 68 MEA T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 69 South Africa T-cell therapy market estimates & forecasts, by modality, 2015 - 2026 (USD Million)
  • TABLE 70 South Africa T-cell therapy market estimates & forecasts, by therapy-type, 2015 - 2026 (USD Million)
  • TABLE 71 South Africa T-cell therapy market estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 72 South Africa T-cell therapy market for hematologic malignancies estimates & forecasts, by indication, 2015 - 2026 (USD Million)
  • TABLE 73 South Africa T-cell therapy market for solid tumors estimates & forecasts, by indication, 2015 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value-chain-based sizing & forecasting
  • FIG. 6 QFD modeling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market segmentation & scope
  • FIG. 9 Market trends & outlook
  • FIG. 10 Penetration & growth prospect mapping for therapy, 2018
  • FIG. 11 Market driver relevance analysis (Current & future impact)
  • FIG. 12 Annual Investment in the CAR-T Space, 2013-2026
  • FIG. 13 Global financings in cell therapy, 2016-2018
  • FIG. 14 Partnerships of selected major companies in CAR T space
  • FIG. 15 Market restraint relevance analysis (Current & future impact)
  • FIG. 16 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
  • FIG. 17 CAR T Cell patent landscape by Derwent World Patents Index (DWPI)
  • FIG. 18 Major leaders in CAR T-cell therapy patent, by Derwent World Patents Index
  • FIG. 19 CAR T Cell patent landscape by Derwent World Patents Index (DWPI)
  • FIG. 20 Licensing, joint venture and research-only oncology deals by volume and value from 2014 to 2018
  • FIG. 21 Adoptive cellular therapy: Clinical trial landscape
  • FIG. 22 Ongoing projects for CAR T-cell therapies
  • FIG. 23 Geographic distribution of gene therapy clinical trials, 2017 & 2018
  • FIG. 24 SWOT analysis, by factor (Political & legal, economic, and technological)
  • FIG. 25 Porter's Five Forces Analysis
  • FIG. 26 T-cell therapy market: Modality outlook key takeaways
  • FIG. 27 Global T-cell therapy market: Modality movement analysis
  • FIG. 28 Global research-based T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 29 Global commercial T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 30 T-cell therapy market: Therapy type outlook key takeaways
  • FIG. 31 Global T-cell therapy market: Therapy type movement analysis
  • FIG. 32 Global CAR T-cell Therapy market, 2015 - 2026 (USD Million)
  • FIG. 33 Global T Cell Receptor (TCR)-based therapy market, 2015 - 2026 (USD Million)
  • FIG. 34 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2015 - 2026 (USD Million)
  • FIG. 35 T-cell therapy market: Indication outlook key takeaways
  • FIG. 36 Global T-cell therapy market: Therapy type movement analysis
  • FIG. 37 Global T-cell therapy market for hematologic malignancies, 2015 - 2026 (USD Million)
  • FIG. 38 Global T-cell therapy market for lymphoma, 2015 - 2026 (USD Million)
  • FIG. 39 Global T-cell therapy market for leukemia, 2015 - 2026 (USD Million)
  • FIG. 40 Global T-cell therapy market for myeloma, 2015 - 2026 (USD Million)
  • FIG. 41 Global T-cell therapy market for solid tumors, 2015 - 2026 (USD Million)
  • FIG. 42 Global T-cell therapy market for melanoma, 2015 - 2026 (USD Million)
  • FIG. 43 Global T-cell therapy market for brain & central nervous system, 2015 - 2026 (USD Million)
  • FIG. 44 Global T-cell therapy market for liver cancer, 2015 - 2026 (USD Million)
  • FIG. 45 Global T-cell therapy market for other cancer forms, 2015 - 2026 (USD Million)
  • FIG. 46 Regional market place: Key takeaway
  • FIG. 47 T-cell therapy regional outlook, 2018 & 2026
  • FIG. 48 North America T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 49 U.S. T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 50 Canada T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 51 Europe T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 52 Germany T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 53 U.K. T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 54 Asia Pacific T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 55 Japan T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 56 China T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 57 Latin America T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 58 Brazil T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 59 MEA T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 60 South Africa T-cell therapy market, 2015 - 2026 (USD Million)
  • FIG. 61 Strategy framework
目次
Product Code: GVR-3-68038-685-1

The global T-cell therapy market size is expected to reach USD 7.51 billion, expanding at a CAGR of 15.4% by 2026, according to a new report by Grand View Research, Inc. The landmark approvals of Yescarta and Kymriah have spurred unprecedented advancements in the market. The launch of these breakthrough therapies has bolstered cash inflow for innovation, thereby driving the growth.

Expansion of the market for T-cell therapy significantly relies on shifting preference from first-line stem cell transplants and chemotherapy to third-line CAR T-cell therapy. Moreover, the ever-expanding plethora of medical conditions for which the T cell therapies is projected to bode well for the market growth. Rise in oncological disorders is projected to drive interest as well as investments in the T-cell therapy market in near future.

In contrast with the small-molecule landscape, engineered T cells market landscape is distinguished by an extensive network that encompasses several entities marked by connections academically, financially, and via technology licensing. Research bodies, and manufacturers, and regulators engage in assessing the long-term efficacy and safety of therapies to ensure safe access to patients.

By far, the antigen challenge and linked toxicity concerns have impeded the development of CAR T therapies in non-hematological malignancies. Market players are applying a data-driven approach of exploring this space to mitigate the challenge and expand the usage of T-cell therapy in indication type such as brain cancer and melanoma.

Further key findings from the report suggest:

  • In the coming years, the number of hospitals implementing CAR T therapies is expected to increase, thereby driving the commercialized business model
  • Research-based business modality accounted for the highest revenue generation over the past years, attributed to the presence of several research programs
  • CAR-T cell therapy market share accounted for the larger revenue share of the overall T-cell therapy market in 2018 owing to the highest investment by sponsors in this therapy type
  • Presence of approved products for B cell lymphoma and acute lymphocytic leukemia has resulted in the dominance of hematological malignancies in the market
  • Therapy for solid tumors is expected to emerge as the lucrative source of revenue generation in the forthcoming years
  • Rising research activities in CAR T-cell therapy for solid tumors, particularly, for brain & central nervous system and melanoma, is expected to benefit the key players
  • North America led the global market in 2018 owing to the presence of a large number of cancer centers engaging in research activities. Moreover, U.S.-based pharma companies like Pfizer Inc. and Celgene Corporation have shifted their focus from conventional drug development to T-cell therapy space
  • Asia Pacific is estimated to witness the fastest growth with China at the forefront. China has surpassed the number of CAR T clinical trials conducted in U.S. Moreover, Novartis is strategizing to secure approval for Kymriah by China regulatory authorities in the forthcoming years
  • Gilead Sciences, Novartis AG, TCR2 Therapeutics Inc., Celgene Corporation, Sorrento Therapeutics, bluebird bio, and Fate Therapeutics are some key players operating in the market. They engage in mergers and acquisitions with therapy developers. Acquisition of Juno Therapeutics by Celgene in January 2018 and Kite Pharma by Gilead in August 2017 are some notable examples of acquisitions in this market

Table of content

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Information or Data Analysis
  • 1.3 Market Formulation & Validation

Chapter 2 Executive Summary

  • 2.1 Competition Milieu
  • 2.2 Market Snapshot
  • 2.3 Segment Outlook

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Penetration & Growth Prospect Mapping for Therapy Type, 2018
  • 3.2 T-Cell Therapy - Market Dynamics
    • 3.2.1 Market driver analysis
      • 3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment
      • 3.2.1.2 Growing competition among market players
      • 3.2.1.3 Approval of Kymriah and Yescarta across various countries
      • 3.2.1.4 Developments in CAR T-cell therapy for solid tumors
      • 3.2.1.5 Technological advancements in manufacturing process
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
      • 3.2.2.2 High prices of therapies
      • 3.2.2.3 CAR T limitations
    • 3.2.3 Opportunity analysis
      • 3.2.3.1 Facility expansion for cell and gene therapies
      • 3.2.3.2 Rising global financings in gene and cell therapy arena
      • 3.2.3.3 Ongoing developments in viral & non-viral vector manufacturing arena
  • 3.3 Regulatory Landscape
    • 3.3.1 Current and potential future approvals
    • 3.3.2 Frameworks for risk mitigation and safety monitoring
    • 3.3.3 Regulatory framework, by geography
      • 3.3.3.1 U.S.
      • 3.3.3.2 Europe
      • 3.3.3.3 China
      • 3.3.3.4 Japan
  • 3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)
    • 3.4.1 Insurance coverage
    • 3.4.2 Value-based price benchmarks
    • 3.4.3 Alternate payment strategies
  • 3.5 Patent Landscape
  • 3.6 Deals, Funding's, Partnerships and Collaborations
    • 3.6.1 Licensing deals
    • 3.6.2 Merger & acquisition deals
    • 3.6.3 Collaboration & partnerships
  • 3.7 Pipeline Analysis
    • 3.7.1 Clinical trial landscape
  • 3.8 Geographic Mapping of Companies
  • 3.9 Competitive Landscape for CD19­directed CAR­T Therapies and Other T-cell therapies
  • 3.10 T-cell Therapy Market-SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
    • 3.10.1 Political landscape
    • 3.10.2 Economic landscape
    • 3.10.3 Social landscape
    • 3.10.4 Technology landscape
  • 3.11 Industry Analysis - Porter's
    • 3.11.1 Supplier bargaining power
    • 3.11.2 Buyer bargaining power
    • 3.11.3 Substitution threat
    • 3.11.4 Threat from new entrant
    • 3.11.5 Competitive rivalry

Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis

  • 4.1 T-cell Therapy Market: Modality Movement Analysis
  • 4.2 Research
    • 4.2.1 Global research-based T-cell therapy market, 2015 - 2026 (USD Million)
  • 4.3 Commercialized
    • 4.3.1 Global commercial T-cell therapy market, 2015 - 2026 (USD Million)

Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis

  • 5.1 T-cell Therapy Market: Therapy Type Movement Analysis
  • 5.2 CAR T-cell Therapy
    • 5.2.1 Global CAR T-cell Therapy market, 2015 - 2026 (USD Million)
  • 5.3 T Cell Receptor (TCR)-based
    • 5.3.1 Global T Cell Receptor (TCR)-based therapy market, 2015 - 2026 (USD Million)
  • 5.4 Tumor Infiltrating Lymphocytes (TIL)-based
    • 5.4.1 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2015 - 2026 (USD Million)

Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis

  • 6.1 T-cell Therapy Market: Indication Movement Analysis
  • 6.2 Hematologic Malignancies
    • 6.2.1 Global T-cell therapy market for hematologic malignancies, 2015 - 2026 (USD Million)
    • 6.2.2 Lymphoma
      • 6.2.2.1 Global T-cell therapy market for lymphoma, 2015 - 2026 (USD Million)
    • 6.2.3 Leukemia
      • 6.2.3.1 Global T-cell therapy market for leukemia, 2015 - 2026 (USD Million)
    • 6.2.4 Myeloma
      • 6.2.4.1 Global T-cell therapy market for myeloma, 2015 - 2026 (USD Million)
  • 6.3 Solid Tumors
    • 6.3.1 Global T-cell therapy market for solid tumors, 2015 - 2026 (USD Million)
    • 6.3.2 Melanoma
      • 6.3.2.1 Global T-cell therapy market for melanoma, 2015 - 2026 (USD Million)
    • 6.3.3 Brain & Central Nervous System
      • 6.3.3.1 Global T-cell therapy market for brain & central nervous system, 2015 - 2026 (USD Million)
    • 6.3.4 Liver cancer
      • 6.3.4.1 Global T-cell therapy market for liver cancer, 2015 - 2026 (USD Million)
    • 6.3.5 Others
      • 6.3.5.1 Global T-cell therapy market for other cancer forms, 2015 - 2026 (USD Million)

Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Use-type & Therapy Type

  • 7.1 T-cell Therapy Market Share by Regional, 2018 & 2026
  • 7.2 North America
    • 7.2.1 North America T-cell therapy market, 2015 - 2026 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. T-cell therapy market, 2015 - 2026 (USD Million), by modality
      • 7.2.2.2 U.S. T-cell therapy market, 2015 - 2026 (USD Million), by therapy type
      • 7.2.2.3 U.S. T-cell therapy market, 2015 - 2026 (USD Million), by indication
    • 7.2.3 Canada
      • 7.2.3.1 Canada T-cell therapy market, 2015 - 2026 (USD Million), by modality
      • 7.2.3.2 Canada T-cell therapy market, 2015 - 2026 (USD Million), by therapy type
      • 7.2.3.3 Canada T-cell therapy market, 2015 - 2026 (USD Million), by indication
  • 7.3 Europe
    • 7.3.1 Europe T-cell therapy market, 2015 - 2026 (USD Million)
    • 7.3.2 Germany
      • 7.3.2.1 Germany T-cell therapy market, 2015 - 2026 (USD Million), by modality
      • 7.3.2.2 Germany T-cell therapy market, 2015 - 2026 (USD Million), by therapy type
      • 7.3.2.3 Germany T-cell therapy market, 2015 - 2026 (USD Million), by indication
    • 7.3.3 U.K.
      • 7.3.3.1 U.K. T-cell therapy market, 2015 - 2026 (USD Million), by modality
      • 7.3.3.2 U.K. T-cell therapy market, 2015 - 2026 (USD Million), by therapy type
      • 7.3.3.3 U.K. T-cell therapy market, 2015 - 2026 (USD Million), by indication
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific T-cell therapy market, 2015 - 2026 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan T-cell therapy market, 2015 - 2026 (USD Million), by modality
      • 7.4.2.2 Japan T-cell therapy market, 2015 - 2026 (USD Million), by therapy type
      • 7.4.2.3 Japan T-cell therapy market, 2015 - 2026 (USD Million), by indication
    • 7.4.3 China
      • 7.4.3.1 China T-cell therapy market, 2015 - 2026 (USD Million), by modality
      • 7.4.3.2 China T-cell therapy market, 2015 - 2026 (USD Million), by therapy type
      • 7.4.3.3 China T-cell therapy market, 2015 - 2026 (USD Million), by indication
  • 7.5 Latin America
    • 7.5.1 Latin America T-cell therapy market, 2015 - 2026 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil T-cell therapy market, 2015 - 2026 (USD Million), by modality
      • 7.5.2.2 Brazil T-cell therapy market, 2015 - 2026 (USD Million), by therapy type
      • 7.5.2.3 Brazil T-cell therapy market, 2015 - 2026 (USD Million), by indication
  • 7.6 MEA
    • 7.6.1 MEA T-cell therapy market, 2015 - 2026 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 Brazil T-cell therapy market, 2016 - 2026 (USD Million), by modality
      • 7.6.2.2 Brazil T-cell therapy market, 2016 - 2026 (USD Million), by therapy type
      • 7.6.2.3 Brazil T-cell therapy market, 2016 - 2026 (USD Million), by indication

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Company Profiles
    • 8.2.1 Novartis AG
      • 8.2.1.1 Company overview
      • 8.2.1.1.1 AveXis, Inc.
      • 8.2.1.2 Financial performance
      • 8.2.1.3 Product benchmarking
      • 8.2.1.4 Strategic initiatives
    • 8.2.2 Gilead Sciences
      • 8.2.2.1 Company overview
      • 8.2.1.1.1 Kite Pharma
      • 8.2.2.2 Financial performance
      • 8.2.2.3 Product benchmarking
      • 8.2.2.4 Strategic initiatives
    • 8.2.3 bluebird bio, Inc.
      • 8.2.3.1 Company overview
      • 8.2.3.2 Financial performance
      • 8.2.3.3 Product benchmarking
      • 8.2.3.4 Strategic initiatives
    • 8.2.4 TCR2 Therapeutics Inc
      • 8.2.4.1 Company overview
      • 8.2.4.2 Financial performance
      • 8.2.4.3 Product benchmarking
      • 8.2.4.4 Strategic initiatives
    • 8.2.5 Sorrento Therapeutics
      • 8.2.5.1 Company overview
      • 8.2.5.2 Product benchmarking
      • 8.2.5.3 Strategic initiatives
    • 8.2.6 Fate Therapeutics
      • 8.2.6.1 Company overview
      • 8.2.6.2 Financial performance
      • 8.2.6.3 Product benchmarking
      • 8.2.6.3 Strategic initiatives
    • 8.2.7 Merck KGaA
      • 8.2.7.1 Company overview
      • 8.2.7.2 Financial performance
      • 8.2.7.3 Product benchmarking
      • 8.2.7.3 Strategic initiatives
    • 8.2.8 Pfizer Inc.
      • 8.2.8.1 Company overview
      • 8.2.8.2 Financial performance
      • 8.2.8.3 Product benchmarking
      • 8.2.8.4 Strategic initiatives
    • 8.2.9 Amgen
      • 8.2.9.1 Company overview
      • 8.2.9.2 Financial performance
      • 8.2.9.3 Product benchmarking
      • 8.2.9.4 Strategic initiatives
    • 8.2.10 Celgene Corporation
      • 8.2.10.1 Company overview
      • 8.2.1.1.1 Juno Therapeutics
      • 8.2.10.2 Financial performance
      • 8.2.10.3 Product benchmarking
      • 8.2.10.4 Strategic initiatives
Back to Top